Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 5/20 | 0.40 |
| ▸ | CCR8 | P51685 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.40 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 4/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544974 | 0.77 | KDM4E (0.40) | L3MBTL1HSP90AA1NPC1LMNACCR1 | |
| SCHEMBL5182523 | 0.75 | LMNA (0.39) | L3MBTL1HSP90AA1NPC1LMNACCR1 | |
| SCHEMBL31167172 | 0.75 | LIMK1 (0.43) | L3MBTL1HSP90AA1NPC1LMNACCR1 | |
| SCHEMBL9541333 | 0.75 | METAP2 (0.45) | L3MBTL1HSP90AA1NPC1LMNACCR1 | |
| SCHEMBL3970053 | 0.75 | HSP90AA1 (0.40) | L3MBTL1HSP90AA1NPC1LMNACCR1 | |
| SCHEMBL5183987 | 0.75 | LIMK1 (0.43) | L3MBTL1HSP90AA1NPC1LMNACCR1 | |
| SCHEMBL8114833 | 0.75 | KDM4E (0.40) | L3MBTL1HSP90AA1NPC1LMNACCR1 | |
| SCHEMBL13857883 | 0.75 | PSMD14 (0.45) | L3MBTL1HSP90AA1NPC1LMNACCR1 | |
| SCHEMBL22430423 | 0.75 | HSP90AA1 (0.35) | L3MBTL1HSP90AA1NPC1LMNACCR1 | |
| SCHEMBL18237974 | 0.75 | SLC40A1 (0.38) | L3MBTL1HSP90AA1NPC1LMNACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019043372-A1 | SUBSTITUTES SULFONYL AZACYCLES AS MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2019-03-07 | — | — | WO | disclosed |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | EFFECTOR THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-9255110-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | ROCHE PALO ALTO LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| WO-2008036541-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-03-27 | — | — | WO | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | L3MBTL1 669/4885HSP90AA1 1663/4885NPC1 577/4885 |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | L3MBTL1 1658/4885HSP90AA1 3693/4885NPC1 2973/4885 |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | L3MBTL1 1658/4885HSP90AA1 3693/4885NPC1 2973/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | L3MBTL1 1658/4885HSP90AA1 3693/4885NPC1 2973/4885 |
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | L3MBTL1 4787/4885HSP90AA1 2147/4885NPC1 905/4885 |
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | MAP3K9, MAP3K19, MAP3K20 | L3MBTL1 3123/4885HSP90AA1 3799/4885NPC1 4242/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | L3MBTL1 4209/4885HSP90AA1 4139/4885NPC1 1470/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | L3MBTL1 1658/4885HSP90AA1 3693/4885NPC1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.